Gabelli has issued a report on Valeant Pharmaceuticals' VRX offer to acquire Cephalon for $73 a share, $5.7 billion total.
According to Gabelli, “Valeant Pharmaceuticals VRX is offering $73 per share for Cephalon ($5.7 billion in total) – call at 8:30am… Cephalon has a strong legacy business, plus a European generics business, which makes it attractive.”
VRX has a Buy Rating and closed yesterday at $44.39.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in